ES3067563T3 - Pulsative gnrh administration for use in treating cognitive disorders - Google Patents
Pulsative gnrh administration for use in treating cognitive disordersInfo
- Publication number
- ES3067563T3 ES3067563T3 ES20722577T ES20722577T ES3067563T3 ES 3067563 T3 ES3067563 T3 ES 3067563T3 ES 20722577 T ES20722577 T ES 20722577T ES 20722577 T ES20722577 T ES 20722577T ES 3067563 T3 ES3067563 T3 ES 3067563T3
- Authority
- ES
- Spain
- Prior art keywords
- gnrh
- mice
- cognitive
- olfactory
- ts65dn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19305550 | 2019-04-30 | ||
| PCT/EP2020/061943 WO2020221821A1 (en) | 2019-04-30 | 2020-04-29 | Pulsative gnrh administration for treating cognitive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3067563T3 true ES3067563T3 (en) | 2026-05-22 |
Family
ID=66625872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20722577T Active ES3067563T3 (en) | 2019-04-30 | 2020-04-29 | Pulsative gnrh administration for use in treating cognitive disorders |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220202895A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3962494B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7779739B2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3962494T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3067563T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020221821A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022136417A1 (en) | 2020-12-22 | 2022-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pulsative gnrh administration for treating food intake related disorders |
| AU2023332041A1 (en) | 2022-09-02 | 2025-02-20 | Leibniz-Institut Für Immuntherapie (Lit) | THERAPEUTIC USE OF THE miR155 SNP rs377265631 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0158683B1 (de) | 1984-04-14 | 1988-10-05 | Ferring Biotechnik GmbH | Vorrichtung zum intermittierenden Applizieren flüssiger Arzneimittel |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| US5013293A (en) | 1987-05-28 | 1991-05-07 | Drug Delivery Systems Inc. | Pulsating transdermal drug delivery system |
| US20080171736A1 (en) * | 2004-12-23 | 2008-07-17 | Gregory Christopher W | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists |
| WO2007041386A2 (en) | 2005-09-30 | 2007-04-12 | Vyteris, Inc. | Pulsatile delivery of gonadotropin-releasing hormone from a pre-loaded integrated electrotransport patch |
| WO2014110549A1 (en) * | 2013-01-14 | 2014-07-17 | The General Hospital Corporation | Methods and assays relating to rnf216 |
| WO2014179139A2 (en) * | 2013-04-30 | 2014-11-06 | Albert Einstein College Of Medicine Of Yeshiva University | TREATMENT OF AGING EFFECTS BY GONADOTROPIN-RELEASING HORMONE, NEUROGENESIS OR BRAIN IKK-β/NF-κΒ INHIBITION |
| WO2017182580A1 (en) | 2016-04-20 | 2017-10-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the diagnosis and the treatment of reproduction-related disorders and methods for contraception |
| CN108837143B (zh) * | 2018-09-29 | 2022-03-01 | 南华大学 | 曲普瑞林的应用 |
-
2020
- 2020-04-29 JP JP2021564303A patent/JP7779739B2/ja active Active
- 2020-04-29 DK DK20722577.2T patent/DK3962494T3/da active
- 2020-04-29 US US17/607,676 patent/US20220202895A1/en active Pending
- 2020-04-29 EP EP20722577.2A patent/EP3962494B1/en active Active
- 2020-04-29 WO PCT/EP2020/061943 patent/WO2020221821A1/en not_active Ceased
- 2020-04-29 ES ES20722577T patent/ES3067563T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7779739B2 (ja) | 2025-12-03 |
| US20220202895A1 (en) | 2022-06-30 |
| DK3962494T3 (da) | 2026-04-07 |
| WO2020221821A1 (en) | 2020-11-05 |
| EP3962494A1 (en) | 2022-03-09 |
| JP2022533011A (ja) | 2022-07-21 |
| EP3962494B1 (en) | 2026-03-04 |